During the past decade, National Clinical Research, Inc conducted 66 clinical trials. In the 10-year time frame, 66 clinical trials started and 71 clinical trials were completed, i.e. on average, 107.6% percent of trials that started reached the finish line to date. In the past 5 years, 25 clinical trials started and 39 clinical trials were completed. i.e. 156% of trials that started reached the finish line.

Out of the total clinical trials conducted in "National Clinical Research, Inc" #1 sponsor was "Pfizer" with 30 trials, followed by "Eli Lilly and Company" with 14 trials sponsored, "Eisai Inc." with 5 trials sponsored, "Hoffmann-La Roche" with 5 trials sponsored and "Biogen" with 5 trials sponsored. Other sponsors include 68 different institutions and companies that sponsored additional 58 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "National Clinical Research, Inc" #1 collaborator was "Alzheimer's Clinical Trials Consortium" with 2 trials as a collaborator, "Biogen" with 2 trials as a collaborator, "Eli Lilly and Company" with 2 trials as a collaborator, "National Institute on Aging (NIA)" with 2 trials as a collaborator and "Alzheimer's Therapeutic Research Institute" with 1 trials as a collaborator. Other collaborators include 18 different institutions and companies that were collaborators in the rest 28 trials.

According to Clinical.Site data, the most researched conditions in "National Clinical Research, Inc" are "Alzheimer's Disease" (12 trials), "Alzheimer Disease" (9 trials), "Hyperlipidemia" (6 trials), "Obesity" (6 trials) and "Dyslipidemia" (5 trials). Many other conditions were trialed in "National Clinical Research, Inc" in a lesser frequency.

Most popular intervention types in "National Clinical Research, Inc" are "Drug" (118 trials), "Biological" (13 trials) and "Other" (13 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (67 trials), "Aducanumab" (4 trials), "Brisdelle (paroxetine mesylate)" (3 trials), "Crenezumab" (3 trials) and "Donanemab" (3 trials). Other intervention names were less common.

The vast majority of trials in "National Clinical Research, Inc" are 114 trials for "All" genders, 14 trials for "Female" genders and 3 trials for "Male" genders.

Currently, there are NaN active trials in "National Clinical Research, Inc". undefined are not yet recruiting, 10 are recruiting, 7 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 89 completed trials in National Clinical Research, Inc, 1 suspended trials, and 20 terminated clinical trials to date.

Out of the total trials that were conducted in National Clinical Research, Inc, 1 "Phase 1" clinical trials were conducted, 52 "Phase 2" clinical trials and 68 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 8 trials, and there were also 4 trials that are defined as “Not Applicable".